Señales en vivo de ORXOY | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 abr 2024 @ 10:02):

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom...

Stats
Volumen de hoy	655.00
Volumen promedio	67.00
Capitalización de mercado	48.23M
EPS	$-0.967 ( 2023-09-30 )
Próxima fecha de ganancias	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.12
ATR14	$0 (0.00%)

Orexo AB (publ) Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Orexo AB (publ) Finanzas

Annual	2023
Ingresos:	$638.80M
Beneficio Bruto:	$472.80M (74.01 %)
EPS:	$-3.73

FY	2023
Ingresos:	$638.80M
Beneficio Bruto:	$472.80M (74.01 %)
EPS:	$-3.73

FY	2022
Ingresos:	$624.30M
Beneficio Bruto:	$521.70M (83.57 %)
EPS:	$-5.17

FY	2021
Ingresos:	$565.00M
Beneficio Bruto:	$486.10M (86.04 %)
EPS:	$-2.13

Financial Reports:

No articles found.

Orexo AB (publ)

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Actualizaciones en tiempo real para Orexo AB (publ) [ORXOY]

Upcoming Earnings Alert